Compare · AXGN vs CHFS
AXGN vs CHFS
Side-by-side comparison of Axogen Inc. (AXGN) and CHF Solutions, Inc. (CHFS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and CHFS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN carries a market cap of $2.29B.
- AXGN has hit the wire 1 time in the past 4 weeks while CHFS has been quiet.
- AXGN has more recent analyst coverage (8 ratings vs 0 for CHFS).
- Company
- Axogen Inc.
- CHF Solutions, Inc.
- Price
- $43.02+1.50%
- -
- Market cap
- $2.29B
- -
- 1M return
- +6.76%
- -
- 1Y return
- +340.28%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- News (4w)
- 1
- 0
- Recent ratings
- 8
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Director Wendell Amy Mcbride exercised 1,647 shares at a strike of $14.85 and sold $70,162 worth of shares (1,647 units at $42.60) (SEC Form 4)
- Director Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04 (SEC Form 4)
- Director Weiler Kathy Johnson exercised 16,344 shares at a strike of $6.95 and sold $720,623 worth of shares (16,344 units at $44.09) (SEC Form 4)
- Chief Marketing Officer Kemp Jens sold $173,761 worth of shares (4,000 units at $43.44), decreasing direct ownership by 5% to 72,451 units (SEC Form 4)
- CFO Hartley Lindsey Marie sold $45,897 worth of shares (1,051 units at $43.67) and exercised 5,463 shares at a strike of $8.24, increasing direct ownership by 7% to 65,146 units (SEC Form 4)
- Sales VP Quackenbush Doris sold $168,720 worth of shares (3,878 units at $43.51), decreasing direct ownership by 4% to 92,416 units (SEC Form 4)
- New insider Quackenbush Doris claimed ownership of 96,294 shares (SEC Form 3)
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
- Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Latest CHFS
- Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant
- Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021
- American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration
- Nuwellis Announces New Appointments to Leadership Team
- Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
- ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
- Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update
- Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021
- CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
- CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits